Class summary at a glance.

Every drug in the Tumor Necrosis Factor Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 10tracked in Part D
CY24 Part D spend: $6.32Bcombined across class
Total Rx claims: 859K158K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Etanercept

Brand: ENBREL · 630K Part D claims (CY24) · 105K beneficiaries · First FDA approval: 2019-06-07

Brand-only (no generics) 1620 plans require PA

Low NADAC$2076.23

→

Avg plan cost$2080.48

Part D spend $5.14B 1× spread, current vs floor

Class share

81%

of class CY24 spend

View profile →

Certolizumab Pegol

Brand: Cimzia · 59K Part D claims (CY24) · 12K beneficiaries · First FDA approval: 2008-04-20

Brand-only (no generics) 339 plans require PA

Low NADAC$6072.51

→

Avg plan cost$6092.45

Part D spend $431.9M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Golimumab

Brand: SIMPONI ARIA · 49K Part D claims (CY24) · 10K beneficiaries · First FDA approval: 2009-04-25

Brand-only (no generics) 64 plans require PA

Low NADAC$12974.52

→

Avg plan cost$12975.88

Part D spend $359.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Infliximab

Brand: REMICADE · 29K Part D claims (CY24) · 7K beneficiaries · First FDA approval: 1998-08-24

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $187.6M

Class share

of class CY24 spend

View profile →

Infliximab-Dyyb

Brand: INFLECTRA · 13K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2016-11-21

Brand-only (no generics) 44 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $70.3M

Class share

of class CY24 spend

View profile →

Adalimumab-Atto

Brand: AMJEVITA · 44K Part D claims (CY24) · 10K beneficiaries · First FDA approval: 2023-01-31

Brand-only (no generics) 21 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $64.2M

Class share

of class CY24 spend

View profile →

Adalimumab-Adaz

Brand: Adalimumab · 12K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2023-07-01

Brand-only (no generics) 54 plans require PA Discontinued

Low NADAC$1593.32

→

Avg plan cost$1593.32

Part D spend $32.5M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Adalimumab-Bwwd

Brand: HADLIMA · 18K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2023-07-01

Brand-only (no generics) 906 plans require PA

Low NADAC$611.35

→

Avg plan cost$940.93

Part D spend $21.4M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Infliximab-Axxq

Brand: AVSOLA · 3K Part D claims (CY24) · 926 beneficiaries · First FDA approval: 2019-12-12

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $9.4M

Class share

of class CY24 spend

View profile →

Adalimumab-Aqvh

Brand: YUSIMRY · 877 Part D claims (CY24) · 186 beneficiaries · First FDA approval: 2023-07-01

Brand-only (no generics)

Low NADAC$604.15

→

Avg plan cost$604.15

Part D spend $1.0M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.